GPS Rebrands as “Thredd” to Reflect Its Unique Position as the Go to Payments Partner of Innovators Worldwide
Global Processing Services, a next generation global payments platform behind the leading fintechs, digital banks, and embedded finance providers across the UK, Europe, Asia, Middle East and North America, has today rebranded as “Thredd,” to reflect the company’s pivotal role in weaving together the different ‘threads’ of the global payments ecosystem to fuel the growth of electronic payments.
With a new leadership team comprising of industry veterans coupled with the backing of future-focused investors, this rebranding signals the next phase of customer partnership and product innovation to bring the aspirations of innovative payments visionaries to life.
Thredd is known for its customer-centred approach to enable payments innovators to launch new card programmes quickly, easily, and cost effectively. Thredd has created a unique niche as a hands-on, modern processor providing reliable digital payment processing capabilities, including real-time, bespoke card management tools, reporting, and world-class fraud prevention technology.
Certified by both Visa and Mastercard, and supporting debit, prepaid and credit programs, Thredd has enabled modern payments issuer processing since 2007 and has earned a reputation as a trusted, reliable and scalable platform.
Today, Thredd’s next-gen platform processes billions of transactions annually and powers over 100 customers across 44 countries and a broad range of use cases. Thredd is the processing partner of choice for an array of verticals, including digital banking, Buy Now Pay Later (BNPL), Travel, and Banking-as-a-Service (BaaS).
One of Thredd’s fastest growing customers today is “financial super app” Curve which allows customers to combine most debit, credit, and loyalty cards into one platform and a linked smart card for payments. Thredd has provided the issuer processing firepower for Curve’s platform since it was founded in 2016, supporting the innovative fintech as it has scaled to over 4 million customers, diversified its products, and expanded into international markets.
“Our rebranding to Thredd marks a new era for our company as we begin the next phase of our growth. We’ve spent the last six months building our management team with industry veterans to expand our platform capabilities and deepen our commitment to serving the needs of the most innovative fintechs and banks in the world, said Kevin Schultz, Chief Executive Officer of Thredd.
“Our new brand reflects our renewed focus on enabling our clients to create a more interconnected, accessible, and seamless payments ecosystem. With our experienced team and owners, we’re confident in our vision to bring our partnership approach to modern payments processing to innovators worldwide.”
Explaining why the name Thredd was chosen, Betsy Samuel, Chief Marketing Officer of Thredd, said: “Our clients, partners and team members have told us that we are the ultimate connector, bringing true partnership to the world of payments. This is our DNA, and we wanted a new name to reflect this special identity as well as our expanding position as a pivotal modern payments processor at the heart of the constantly evolving digital economy. We are proud to relaunch with a name which reflects our unique role and reputation as a critical ‘thread’ of the fabric in the ecosystem.”
Thredd is backed by an experienced private equity consortium with specialist experience in scaling payments-related tech businesses, including Advent International, Viking Global Investors, Temasek, and MissionOG; with institutional investors including Mastercard and Visa.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230427005429/en/
Contact information
Media:
Louisa Bartoszek
Head of Communications
louisa.bartoszek@thredd.com
Cognito Media
thredd@cognitomedia.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom